Role of macrophage protection in the development of murine AIDS

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 21, Issue 2, 1999, Pages 81-89

  Fraternale, A ^a   Tonelli, A ^a   Casabianca, A ^a   Vallanti, G ^a   Chiarantini, L ^a   Schiavano, G F ^a   Benatti, U ^b   De Flora, A ^b   Magnani, Mauro ^a  

^a UNIVERSITY OF URBINO   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

AZTp2AZT; Drug delivery system; GSH; Macrophages; Murine retrovirus induced immunodeficiency; Triple combination therapy

Indexed keywords

ANTIVIRUS AGENT; GLUTATHIONE; MITOGENIC AGENT; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG MECHANISM; ERYTHROCYTE; FEMALE; INTRAPERITONEAL DRUG ADMINISTRATION; LYMPHOCYTE DEPLETION; MACROPHAGE FUNCTION; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; T LYMPHOCYTE; TREATMENT OUTCOME; VIRUS REPLICATION;

ANIMALS; ANTI-HIV AGENTS; BRAIN; CD4-CD8 RATIO; DISEASE PROGRESSION; DNA, VIRAL; DRUG CARRIERS; DRUG THERAPY, COMBINATION; ERYTHROCYTES; FEMALE; GLUTATHIONE; KIDNEY; LIVER; LYMPHOCYTES; LYMPHOID TISSUE; MACROPHAGES; MICE; MICE, INBRED C57BL; MITOGENS; MURINE ACQUIRED IMMUNODEFICIENCY SYNDROME; THYMINE NUCLEOTIDES; ZIDOVUDINE;

ANIMALIA; MURINAE; UNIDENTIFIED RETROVIRUS;

EID: 0033151578     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Magnani M, Rossi L, Chiarantini L, Fraternale A, Casabianca A. Red blood cells as carriers of drugs against retroviruses. Targeting of Drugs 1994;4:147-52.
2. Gartner S, Markovits P, Markovits D, et al. The role of mononuclear phagocytes in HTLV-III/LAV infection. Science 1986; 233:215-9.
3. Gendelman HE, Orenstein JM, Martin MA, et al. Efficient isolation and propagation of human immunodeficiency virus on recombinant colony-stimulating factor I-treated monocytes. J Exp Med 1988;167:1428-41.
4. Koenig S, Gendelman HE, Orenstein JM, et al. Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy. Science 1986;233:1089-93.
5. Meltzer MS, Gendelman HE. Mononuclear phagocytes as targets, tissue reservoirs, and immunoregulatory cells in human immunodeficiency virus disease. Curr Top Microbiol Immunol 1992;181: 239-63.
6. Cheng-Mayer C, Shioda T, Levy JA. Host range, replicative, and cytopathic properties of human immunodeficiency virus type 1 are determined by very few amino acid changes in Tat and gp 120. J Virol 1991;65:6931-41.
7. Hwang SS, Boyle TJ, Lyerly HK, Cullen BR. Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1. Science 1991;253:71-4.
8. + cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996;381:667-73.
9. Doranz JB, Rucker J, Yi Y, et al. A dual-tropic primary HIV-isolate that uses fusin and the β-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 1996;85:1149-58.
10. Deng H, Liu R, Ellmeier W, et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996;381:661-6.
11. Alkhatib G, Combadiere C, Broder C, et al. CC CKR5: a RANTES, MIP-1α, MIP-1β receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 1996;272:1955-8.
12. Schuitemaker H. Macrophage tropic HIV-1 variants: initiators of infection and AIDS pathogenesis. J Leukocyte Biol 1994;56:218-24.
13. Mosier D, Sieburg H. Macrophage-tropic HIV: critical for AIDS pathogenesis? Immunol Today 1994;15(7):332-9.
14. Embretson J, Zupancic M, Ribas JL, et al. Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature 1993;362:359-62.
15. Pantaleo G, Graziosi C, Demerest J, et al. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 1993;362:355-8.
16. Gill V, Shattock RJ, Freedman AR, et al. Macrophages are the major target for HIV infection in long-term bone marrow culture and demonstrate dual susceptibility to lymphocytotropic and monocytotropic strains of HIV-1. Br J Haematol 1996;93:30-7.
17. Knight SC, Macatonia SE. Effect of HIV on antigen presentation by dendritic cells and macrophages. Res Virol 1991;142:123-8.
18. Wehle K, Schirmer M, Dunnebacke HJ, Kupper T, Pfitzer P. Quantitative differences in phagocytosis and degradation of Pneumocystis carinii by alveolar macrophages in AIDS and non-HIV patients in vivo. Cytopathology 1993;4:231-6.
19. Poli G, Fauci AS. In Aggarwal BB, Puri RK, eds. Human cytokines: their role in disease and therapy. Cambridge, MA: Blackwell Science, 1995:421-49.
20. H2 predominance in HIV-infected individuals. Science 1994;265:248-52.
21. Gallo P, Frei K, Rordorf C, Lazdins J, Tavolato B, Fontana A. Human immunodeficiency virus type 1 (HIV) infection of the central nervous system: an evaluation of cytokines in cerebrospinal fluid. J Neuroimmunol 1989;23:109-16.
22. Glass JD, Johnson RT. Human immunodeficiency virus and the brain. Annu Rev Neurosci 1996;19:1-26.
23. Magnani M, Rossi L, Fraternale A, et al. Targeting antiviral nucleotide analogues to macrophages. J Leukocyte Biol 1997;62: 133-7.
24. Turrini F, Arese P, Yuan J, Low PS. Clustering of integral membrane proteins of the human erythrocyte membrane stimulates autologous IgG binding, complement deposition and phagocytosis. J Biol Chem 1991;266:23611-17.
25. Magnani M, Rossi L, Brandi G, Schiavano GF, Montroni M, Piedimonte G. Targeting antiretroviral nucleoside analogues in phosphorylated form to macrophages: in vitro and in vivo studies. Proc Natl Acad Sci USA 1992;89:6477-81.
26. Perno CF, Yarchoan R, Cooney DA, et al. Inhibition of human immunodeficiency virus (HIV-1/HTLV-III Ba-L) replication in fresh and cultured human peripheral blood monocyte/macrophages by azidothymidine and related 2′,3′-dideoxynucleosides. J Exp Med 1988;168:1111-25.
27. Richman DD, Kornbluth RS, Carson DA. Failure of dideoxynucleosides to inhibit human immunodeficiency virus replication in cultured human macrophages. J Exp Med 1987;166:1144-9.
28. Magnani M, Casabianca A, Fraternale A, et al. Synthesis and targeted delivery of an azidothymidine homodinucleotide conferring protection to macrophages against retroviral infection. Proc Natl Acad Sci USA 1996;93:4403-8.
29. Magnani M, Rossi L, Fraternale A, et al. Feline immunodeficiency virus infection of macrophages: in vitro and in vivo inhibition by dideoxycytidine-5′-triphosphate-loaded erythrocytes. AIDS Res Hum Retroviruses 1994;10:1179-86.
30. Magnani M, Casabianca A, Fraternale A, et al. Inhibition of murine AIDS by a new azidothymidine homodinucleotide. J Acquir Immun Defic Syndr Hum Retrovirol 1998;17:189-95.
31. Jolicoeur P. Murine acquired immunodeficiency syndrome (MAIDS): an animal model to study the AIDS pathogenesis. FASEB J 1991;5:2398-405.
32. Morse HC III, Chattopadhyay SK, Makino M, Fredrikson TN, Hugin AW, Hartley JW. Retrovirus-induced immunodeficiency in the mouse: MAIDS as a model for AIDS. AIDS 1992;6:607-21.
33. Chattopadhyay SK, Sengupta DN, Fredrickson TN, Morse HC III, Hartley JW. Characteristics and contributions of detective, ecotropic, and mink cell focus-inducing viruses involved in a retrovirus-induced immunodeficiency syndrome of mice. J Virol 1991; 65:4232-41.
34. Palamara AT, Garaci E, Rotilio G, et al. Inhibition of murine AIDS by reduced glutathione. AIDS Res Hum Retroviruses 1996;12: 1373-81.
35. Vella S. Rationale and experience with reverse transcriptase inhibitors and protease inhibitors. J Acquir Immune Defic Syndr Hum Retrovirol 1995;10:58-61.
36. Collier AC, Coombs RW, Choenfeld DA, et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. N Engl J Med 1996;334:1011-7.
37. Kaufmann JR, Duncombe C, Cunningham P, et al. Treatment response and durability of double protease inhibitor therapy with saquinavir and ritonavir in an observational cohort of HIV-1-infected individuals. AIDS 1998;12:1625-30.
38. Reijers MH, Weverling GJ, Jurriaans S, et al. Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication (ADAM) study. Lancer 1998;352:185-90.
39. Mosier DE, Yetter RA, Morse HCIII. Functional T lymphocytes are required for a murine retrovirus induced immunodeficiency (MAIDS). J Exp Med 1987;165:1737-42.
40. Casabianca A, Vallanti G, Magnani M. Competitive PCR for quantification of BM5d proviral DNA in mice with AIDS. J Clin Microbiol 1998;36:2371-4.
41. Fraternale A, Casabianca A, Rossi L, et al. Inhibition of murine AIDS by combination of AZT and dideoxycytidine-5′-triphosphate. J Acquir Immun Defic Syndr Hum Retrovirol 1996; 12:164-73.
42. Rossi L, Brandi G, Schiavano GF, Chiarantini L, Albano A, Magnani M. In vitro and in vivo toxicity of 2′,3′-dideoxycytidine in mice. Chem Biol Inter 1992;85:255-263.
43. Chau F, Levacher-Clergeot M, Desforges B, Ricatte L, Sinet M. Prognostic value of phenotypic alterations in blood lymphocyte subsets in a murine retrovirus-induced immunodeficiency syndrome (MAIDS). Clin Exp Immunol 1993;91:467-72.
44. Kalebic T, Kinler A, Poli G, Anderson ME, Meister A, Fauci AS. Suppression of human immunodeficiency virus expression in chronically infected monocytic cells by glutathione, glutathione ester, and N-acetylcysteine. Proc Natl Acad Sci USA 1991;88:986-90.
45. Palamara AT, Perno CF, Ciriolo MR, et al. Evidence for antiviral activity of glutathione: in vivo inhibition of herpes simplex virus type 1 replication. Antiviral Res 1995;27:237-53.
46. Palamara AT, Perno CF, Aquaro S, Buè MC, Dini L, Garaci E. Glutathione inhibits HIV replication by acting at late stages of the virus life cycle. AIDS Res Hum Retroviruses 1996;12:1537-41.
47. Staal FS, Roederer M, Herzenberg LA, Herzenberg LA. Intracellular thiols regulate activation of nuclear factor kB and transcription of human immunodeficiency virus. Proc Natl Acad Sci USA 1990;87:9943-7.
48. Mihm S, Galter D, Droge W. Modulation of transcription factor NFkB activity by intracellular glutathione levels and by variations of the extracellular cysteine supply. FASEB J 1995;9:246-52.
49. Magnani M, Fraternale A, Casabianca A, et al. Antiretroviral effect of combined zidovudine and reduced glutathione therapy in murine AIDS. AIDS Res Hum Retroviruses 1997;13:1093-9.